Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics

Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. However, how to accurately evaluate the risk of breast cancer recurrence and metastasis after adjuvant TAM therapy is still a major concern. In recent years, many studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Hui, Zhang, Guoqiang, Yan, Na, Lang, Jidong, Liang, Yuebin, Xu, Xinyuan, Cui, Yaowen, Wu, Xueya, Li, Xianjun, Shan, Ming, Wang, Xiaoqin, Meng, Xiangzhi, Liu, Jiaxiang, Tian, Geng, Cai, Li, Yuan, Dawei, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639703/
https://www.ncbi.nlm.nih.gov/pubmed/34868931
http://dx.doi.org/10.3389/fonc.2021.738222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639703/
https://www.ncbi.nlm.nih.gov/pubmed/34868931
http://dx.doi.org/10.3389/fonc.2021.738222

Ejemplares similares